Annual CFO
$127.04 M
+$6.72 M+5.58%
December 31, 2023
Summary
- As of February 7, 2025, CORT annual cash flow from operations is $127.04 million, with the most recent change of +$6.72 million (+5.58%) on December 31, 2023.
- During the last 3 years, CORT annual CFO has fallen by -$24.93 million (-16.41%).
- CORT annual CFO is now -24.33% below its all-time high of $167.89 million, reached on December 31, 2021.
Performance
CORT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
$73.83 M
+$32.65 M+79.27%
September 30, 2024
Summary
- As of February 7, 2025, CORT quarterly cash flow from operations is $73.83 million, with the most recent change of +$32.65 million (+79.27%) on September 30, 2024.
- Over the past year, CORT quarterly CFO has increased by +$50.07 million (+210.78%).
- CORT quarterly CFO is now at all-time high.
Performance
CORT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
$144.65 M
+$20.92 M+16.91%
September 30, 2024
Summary
- As of February 7, 2025, CORT TTM cash flow from operations is $144.65 million, with the most recent change of +$20.92 million (+16.91%) on September 30, 2024.
- Over the past year, CORT TTM CFO has increased by +$19.82 million (+15.87%).
- CORT TTM CFO is now -18.60% below its all-time high of $177.72 million, reached on March 31, 2022.
Performance
CORT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
CORT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.6% | +210.8% | +15.9% |
| 3 y3 years | -16.4% | +121.1% | +20.2% |
| 5 y5 years | +9.8% | +121.1% | +20.2% |
CORT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -24.3% | +5.6% | at high | +1154.1% | -18.6% | +30.3% |
| 5 y | 5-year | -24.3% | +5.6% | at high | +1154.1% | -18.6% | +30.3% |
| alltime | all time | -24.3% | +442.8% | at high | +739.0% | -18.6% | +473.2% |
Corcept Therapeutics Incorporated Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $73.83 M(+79.3%) | $144.65 M(+16.9%) |
| Jun 2024 | - | $41.18 M(+73.4%) | $123.73 M(-0.9%) |
| Mar 2024 | - | $23.76 M(+303.5%) | $124.84 M(-1.7%) |
| Dec 2023 | $127.04 M(+5.6%) | $5.89 M(-88.9%) | $127.04 M(-17.8%) |
| Sep 2023 | - | $52.91 M(+25.1%) | $154.54 M(+14.2%) |
| Jun 2023 | - | $42.29 M(+62.9%) | $135.28 M(+21.8%) |
| Mar 2023 | - | $25.96 M(-22.3%) | $111.03 M(-7.7%) |
| Dec 2022 | $120.32 M(-28.3%) | $33.39 M(-0.8%) | $120.32 M(-11.8%) |
| Sep 2022 | - | $33.65 M(+86.5%) | $136.36 M(-9.9%) |
| Jun 2022 | - | $18.04 M(-48.8%) | $151.42 M(-14.8%) |
| Mar 2022 | - | $35.25 M(-28.7%) | $177.72 M(+5.9%) |
| Dec 2021 | $167.89 M(+10.5%) | $49.43 M(+1.5%) | $167.89 M(+9.4%) |
| Sep 2021 | - | $48.70 M(+9.8%) | $153.54 M(+13.5%) |
| Jun 2021 | - | $44.34 M(+74.4%) | $135.28 M(-6.1%) |
| Mar 2021 | - | $25.42 M(-27.5%) | $144.12 M(-5.2%) |
| Dec 2020 | $151.97 M(+11.6%) | $35.07 M(+15.2%) | $151.97 M(-8.1%) |
| Sep 2020 | - | $30.44 M(-42.8%) | $165.35 M(-4.6%) |
| Jun 2020 | - | $53.19 M(+59.9%) | $173.34 M(+19.0%) |
| Mar 2020 | - | $33.27 M(-31.3%) | $145.71 M(+7.0%) |
| Dec 2019 | $136.12 M(+17.7%) | $48.45 M(+26.1%) | $136.12 M(+24.7%) |
| Sep 2019 | - | $38.43 M(+50.4%) | $109.18 M(-5.3%) |
| Jun 2019 | - | $25.55 M(+7.9%) | $115.26 M(+9.9%) |
| Mar 2019 | - | $23.68 M(+10.0%) | $104.92 M(-9.3%) |
| Dec 2018 | $115.67 M(+89.8%) | $21.52 M(-51.6%) | $115.67 M(-2.8%) |
| Sep 2018 | - | $44.51 M(+192.6%) | $119.03 M(+39.3%) |
| Jun 2018 | - | $15.21 M(-55.8%) | $85.45 M(-0.4%) |
| Mar 2018 | - | $34.43 M(+38.4%) | $85.80 M(+40.8%) |
| Dec 2017 | $60.94 M(+231.3%) | $24.88 M(+127.8%) | $60.94 M(+50.0%) |
| Sep 2017 | - | $10.93 M(-29.8%) | $40.62 M(+5.2%) |
| Jun 2017 | - | $15.57 M(+62.8%) | $38.63 M(+56.7%) |
| Mar 2017 | - | $9.56 M(+109.3%) | $24.66 M(+34.1%) |
| Dec 2016 | $18.39 M(+487.6%) | $4.57 M(-48.9%) | $18.39 M(+2.3%) |
| Sep 2016 | - | $8.94 M(+461.9%) | $17.98 M(+81.1%) |
| Jun 2016 | - | $1.59 M(-51.8%) | $9.93 M(+21.1%) |
| Mar 2016 | - | $3.30 M(-20.8%) | $8.20 M(+162.1%) |
| Dec 2015 | $3.13 M(-111.4%) | $4.16 M(+371.5%) | $3.13 M(-228.5%) |
| Sep 2015 | - | $883.00 K(-735.3%) | -$2.44 M(-73.7%) |
| Jun 2015 | - | -$139.00 K(-92.2%) | -$9.25 M(-48.9%) |
| Mar 2015 | - | -$1.78 M(+26.7%) | -$18.09 M(-33.9%) |
| Dec 2014 | -$27.38 M(-26.1%) | -$1.40 M(-76.3%) | -$27.38 M(-18.6%) |
| Sep 2014 | - | -$5.93 M(-34.0%) | -$33.64 M(-7.4%) |
| Jun 2014 | - | -$8.98 M(-18.8%) | -$36.31 M(-0.7%) |
| Mar 2014 | - | -$11.06 M(+44.3%) | -$36.56 M(-1.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$37.06 M(+2.9%) | -$7.67 M(-10.9%) | -$37.06 M(-2.8%) |
| Sep 2013 | - | -$8.60 M(-6.9%) | -$38.13 M(-1.6%) |
| Jun 2013 | - | -$9.24 M(-20.1%) | -$38.76 M(+3.6%) |
| Mar 2013 | - | -$11.55 M(+32.2%) | -$37.42 M(+3.9%) |
| Dec 2012 | -$36.02 M(+31.5%) | -$8.74 M(-5.3%) | -$36.02 M(+7.3%) |
| Sep 2012 | - | -$9.23 M(+16.9%) | -$33.57 M(+8.5%) |
| Jun 2012 | - | -$7.89 M(-22.3%) | -$30.95 M(+2.3%) |
| Mar 2012 | - | -$10.16 M(+61.4%) | -$30.26 M(+10.4%) |
| Dec 2011 | -$27.40 M(+23.0%) | -$6.29 M(-4.7%) | -$27.40 M(+3.2%) |
| Sep 2011 | - | -$6.60 M(-8.4%) | -$26.56 M(+0.7%) |
| Jun 2011 | - | -$7.21 M(-1.2%) | -$26.38 M(+11.4%) |
| Mar 2011 | - | -$7.29 M(+33.7%) | -$23.69 M(+6.3%) |
| Dec 2010 | -$22.29 M(+24.0%) | -$5.46 M(-15.1%) | -$22.29 M(+5.1%) |
| Sep 2010 | - | -$6.43 M(+42.3%) | -$21.21 M(+14.6%) |
| Jun 2010 | - | -$4.52 M(-23.3%) | -$18.51 M(-8.3%) |
| Mar 2010 | - | -$5.89 M(+34.4%) | -$20.19 M(+12.4%) |
| Dec 2009 | -$17.97 M(-2.1%) | -$4.38 M(+17.5%) | -$17.97 M(-0.6%) |
| Sep 2009 | - | -$3.73 M(-39.8%) | -$18.08 M(-1.2%) |
| Jun 2009 | - | -$6.20 M(+69.1%) | -$18.30 M(+4.3%) |
| Mar 2009 | - | -$3.66 M(-18.5%) | -$17.56 M(-4.4%) |
| Dec 2008 | -$18.36 M(+67.5%) | -$4.49 M(+13.7%) | -$18.36 M(+7.5%) |
| Sep 2008 | - | -$3.95 M(-27.5%) | -$17.09 M(+17.9%) |
| Jun 2008 | - | -$5.45 M(+21.9%) | -$14.50 M(+22.7%) |
| Mar 2008 | - | -$4.47 M(+38.8%) | -$11.81 M(+7.7%) |
| Dec 2007 | -$10.96 M(-52.8%) | -$3.22 M(+135.9%) | -$10.96 M(-17.5%) |
| Sep 2007 | - | -$1.36 M(-50.6%) | -$13.29 M(-23.6%) |
| Jun 2007 | - | -$2.76 M(-23.8%) | -$17.39 M(-17.8%) |
| Mar 2007 | - | -$3.62 M(-34.7%) | -$21.15 M(-9.0%) |
| Dec 2006 | -$23.24 M(+34.8%) | -$5.54 M(+1.5%) | -$23.24 M(+8.3%) |
| Sep 2006 | - | -$5.46 M(-16.3%) | -$21.46 M(+10.9%) |
| Jun 2006 | - | -$6.52 M(+14.2%) | -$19.35 M(+12.3%) |
| Mar 2006 | - | -$5.71 M(+51.7%) | -$17.23 M(-0.0%) |
| Dec 2005 | -$17.23 M(+25.6%) | -$3.77 M(+12.4%) | -$17.23 M(-6.2%) |
| Sep 2005 | - | -$3.35 M(-23.9%) | -$18.37 M(-0.5%) |
| Jun 2005 | - | -$4.40 M(-23.0%) | -$18.46 M(+7.3%) |
| Mar 2005 | - | -$5.71 M(+16.6%) | -$17.21 M(+25.4%) |
| Dec 2004 | -$13.72 M(+37.1%) | -$4.90 M(+42.6%) | -$13.72 M(+32.6%) |
| Sep 2004 | - | -$3.44 M(+9.1%) | -$10.34 M(+17.3%) |
| Jun 2004 | - | -$3.15 M(+41.6%) | -$8.82 M(-3.6%) |
| Mar 2004 | - | -$2.23 M(+45.6%) | -$9.14 M(-8.6%) |
| Dec 2003 | -$10.00 M | -$1.53 M(-20.1%) | -$10.00 M(+18.0%) |
| Sep 2003 | - | -$1.91 M(-45.0%) | -$8.47 M(+29.1%) |
| Jun 2003 | - | -$3.48 M(+12.7%) | -$6.56 M(+112.7%) |
| Mar 2003 | - | -$3.09 M | -$3.09 M |
FAQ
- What is Corcept Therapeutics Incorporated annual cash flow from operations?
- What is the all time high annual CFO for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated annual CFO year-on-year change?
- What is Corcept Therapeutics Incorporated quarterly cash flow from operations?
- What is the all time high quarterly CFO for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated quarterly CFO year-on-year change?
- What is Corcept Therapeutics Incorporated TTM cash flow from operations?
- What is the all time high TTM CFO for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated TTM CFO year-on-year change?
What is Corcept Therapeutics Incorporated annual cash flow from operations?
The current annual CFO of CORT is $127.04 M
What is the all time high annual CFO for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high annual cash flow from operations is $167.89 M
What is Corcept Therapeutics Incorporated annual CFO year-on-year change?
Over the past year, CORT annual cash flow from operations has changed by +$6.72 M (+5.58%)
What is Corcept Therapeutics Incorporated quarterly cash flow from operations?
The current quarterly CFO of CORT is $73.83 M
What is the all time high quarterly CFO for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high quarterly cash flow from operations is $73.83 M
What is Corcept Therapeutics Incorporated quarterly CFO year-on-year change?
Over the past year, CORT quarterly cash flow from operations has changed by +$50.07 M (+210.78%)
What is Corcept Therapeutics Incorporated TTM cash flow from operations?
The current TTM CFO of CORT is $144.65 M
What is the all time high TTM CFO for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high TTM cash flow from operations is $177.72 M
What is Corcept Therapeutics Incorporated TTM CFO year-on-year change?
Over the past year, CORT TTM cash flow from operations has changed by +$19.82 M (+15.87%)